PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript

PetVivo Holdings, Inc. (OTCPK:PETV) reported preliminary, unaudited fiscal year 2025 results, noting all financial figures are subject to change pending the completion of their Form 10-K audit, for which an extension was filed. Despite the audit delay, management characterized the year as "strong and very productive," driven by expanded adoption of their lead animal osteoarthritis device, Spryng, and the addition of new diagnostic and medical treatment technologies through recent partnerships.

Analysis

PetVivo Holdings (PETV) presented a positive operational narrative for its fiscal year 2025, which concluded on March 31, 2025, citing expanded adoption of its lead veterinary medical device, Spryng, and the strengthening of its technology platform through new partnerships in diagnostics and medical treatments. Management characterized the year as 'strong and very productive,' aligning with the optimistic tone of the call. However, this positive outlook is significantly caveated by a material disclosure: the company has filed for an extension to submit its Form 10-K, rendering all discussed financial results as preliminary, unaudited, and subject to change. The delay, required to allow auditors to complete their work, introduces a notable layer of uncertainty and risk, temporarily overshadowing the company's reported operational progress until finalized, audited financials are available for review.

Key Decisions for Investors

• Investors should exercise caution and treat management's optimistic commentary with skepticism until the audited Form 10-K is filed, as the delay introduces significant uncertainty and the preliminary figures are subject to material change.
• The primary catalyst to monitor is the filing of the Form 10-K; upon its release, scrutinize any discrepancies between preliminary and audited results and review auditor notes for any red flags or 'going concern' language.
• While awaiting financial clarity, evaluate the qualitative progress on the adoption of the Spryng device and the potential revenue contribution from new partnerships, as these are the core tenets of the company's growth story.